181 related articles for article (PubMed ID: 32206108)
21. Renal cancer cells lacking hypoxia inducible factor (HIF)-1alpha expression maintain vascular endothelial growth factor expression through HIF-2alpha.
Shinojima T; Oya M; Takayanagi A; Mizuno R; Shimizu N; Murai M
Carcinogenesis; 2007 Mar; 28(3):529-36. PubMed ID: 16920734
[TBL] [Abstract][Full Text] [Related]
22. Numerical analysis of apparent decitabine uptake in HCT116 cells: Incorporation of a bidirectional first-order kinetic parameter for ENT1 transport and Michaelis-Menten parameters for subsequent phosphorylation.
Ueda K; Nakamura T; Tanaka S; Hosokawa M; Iwakawa S; Ogawara KI
Drug Metab Pharmacokinet; 2020 Feb; 35(1):124-130. PubMed ID: 31964620
[TBL] [Abstract][Full Text] [Related]
23. Decitabine exerted synergistic effects with oxaliplatin in colorectal cancer cells with intrinsic resistance to decitabine.
Hosokawa M; Tanaka S; Ueda K; Iwakawa S; Ogawara KI
Biochem Biophys Res Commun; 2019 Jan; 509(1):249-254. PubMed ID: 30581001
[TBL] [Abstract][Full Text] [Related]
24. HIF-1α inhibition reverses multidrug resistance in colon cancer cells via downregulation of MDR1/P-glycoprotein.
Chen J; Ding Z; Peng Y; Pan F; Li J; Zou L; Zhang Y; Liang H
PLoS One; 2014; 9(6):e98882. PubMed ID: 24901645
[TBL] [Abstract][Full Text] [Related]
25. Decitabine induces G2/M cell cycle arrest by suppressing p38/NF-κB signaling in human renal clear cell carcinoma.
Shang D; Han T; Xu X; Liu Y
Int J Clin Exp Pathol; 2015; 8(9):11140-8. PubMed ID: 26617834
[TBL] [Abstract][Full Text] [Related]
26. Potential role of polymorphisms in the transporter genes ENT1 and MATE1/OCT2 in predicting TAS-102 efficacy and toxicity in patients with refractory metastatic colorectal cancer.
Suenaga M; Schirripa M; Cao S; Zhang W; Yang D; Dadduzio V; Salvatore L; Borelli B; Pietrantonio F; Ning Y; Okazaki S; Berger MD; Miyamoto Y; Gopez R; Barzi A; Yamaguchi T; Loupakis F; Lenz HJ
Eur J Cancer; 2017 Nov; 86():197-206. PubMed ID: 28992563
[TBL] [Abstract][Full Text] [Related]
27. Inactivation of bone morphogenetic protein 2 may predict clinical outcome and poor overall survival for renal cell carcinoma through epigenetic pathways.
Mitsui Y; Hirata H; Arichi N; Hiraki M; Yasumoto H; Chang I; Fukuhara S; Yamamura S; Shahryari V; Deng G; Saini S; Majid S; Dahiya R; Tanaka Y; Shiina H
Oncotarget; 2015 Apr; 6(11):9577-91. PubMed ID: 25797254
[TBL] [Abstract][Full Text] [Related]
28. Aberrant DNA methylation but not mutation of CITED4 is associated with alteration of HIF-regulated genes in breast cancer.
Huang KT; Takano EA; Mikeska T; Byrne DJ; Dobrovic A; Fox SB
Breast Cancer Res Treat; 2011 Nov; 130(1):319-29. PubMed ID: 21755341
[TBL] [Abstract][Full Text] [Related]
29. Upregulation of miR-489-3p and miR-630 inhibits oxaliplatin uptake in renal cell carcinoma by targeting OCT2.
Chen L; Chen L; Qin Z; Lei J; Ye S; Zeng K; Wang H; Ying M; Gao J; Zeng S; Yu L
Acta Pharm Sin B; 2019 Sep; 9(5):1008-1020. PubMed ID: 31649850
[TBL] [Abstract][Full Text] [Related]
30. Up-regulation of hypoxia-inducible factor 2alpha in renal cell carcinoma associated with loss of Tsc-2 tumor suppressor gene.
Liu MY; Poellinger L; Walker CL
Cancer Res; 2003 May; 63(10):2675-80. PubMed ID: 12750296
[TBL] [Abstract][Full Text] [Related]
31. The novel histone deacetylase inhibitor, N-hydroxy-7-(2-naphthylthio) hepatonomide, exhibits potent antitumor activity due to cytochrome-c-release-mediated apoptosis in renal cell carcinoma cells.
Park KC; Heo JH; Jeon JY; Choi HJ; Jo AR; Kim SW; Kwon HJ; Hong SJ; Han KS
BMC Cancer; 2015 Jan; 15():19. PubMed ID: 25613585
[TBL] [Abstract][Full Text] [Related]
32. Effects of YC-1 on hypoxia-inducible factor 1 alpha in hypoxic human bladder transitional carcinoma cell line T24 cells.
Li Y; Zhao X; Tang H; Zhong Z; Zhang L; Xu R; Li S; Wang Y
Urol Int; 2012; 88(1):95-101. PubMed ID: 22041818
[TBL] [Abstract][Full Text] [Related]
33. Pan-PI-3 kinase inhibitor SF1126 shows antitumor and antiangiogenic activity in renal cell carcinoma.
Joshi S; Singh AR; Durden DL
Cancer Chemother Pharmacol; 2015 Mar; 75(3):595-608. PubMed ID: 25578041
[TBL] [Abstract][Full Text] [Related]
34. Gramicidin A blocks tumor growth and angiogenesis through inhibition of hypoxia-inducible factor in renal cell carcinoma.
David JM; Owens TA; Inge LJ; Bremner RM; Rajasekaran AK
Mol Cancer Ther; 2014 Apr; 13(4):788-99. PubMed ID: 24493697
[TBL] [Abstract][Full Text] [Related]
35. 5-aza-2'-deoxycytidine enhances susceptibility of renal cell carcinoma to paclitaxel by decreasing LEF1/phospho-β-catenin expression.
Shang D; Liu Y; Xu X; Han T; Tian Y
Cancer Lett; 2011 Dec; 311(2):230-6. PubMed ID: 21880414
[TBL] [Abstract][Full Text] [Related]
36. Reversal of drug resistance in human tumor xenografts by 2'-deoxy-5-azacytidine-induced demethylation of the hMLH1 gene promoter.
Plumb JA; Strathdee G; Sludden J; Kaye SB; Brown R
Cancer Res; 2000 Nov; 60(21):6039-44. PubMed ID: 11085525
[TBL] [Abstract][Full Text] [Related]
37. Combination of azacytidine and curcumin is a potential alternative in decitabine-resistant colorectal cancer cells with attenuated deoxycytidine kinase.
Hosokawa M; Seiki R; Iwakawa S; Ogawara KI
Biochem Biophys Res Commun; 2021 Nov; 578():157-162. PubMed ID: 34571370
[TBL] [Abstract][Full Text] [Related]
38. Decitabine induces delayed reactive oxygen species (ROS) accumulation in leukemia cells and induces the expression of ROS generating enzymes.
Fandy TE; Jiemjit A; Thakar M; Rhoden P; Suarez L; Gore SD
Clin Cancer Res; 2014 Mar; 20(5):1249-58. PubMed ID: 24423613
[TBL] [Abstract][Full Text] [Related]
39. BTG3 tumor suppressor gene promoter demethylation, histone modification and cell cycle arrest by genistein in renal cancer.
Majid S; Dar AA; Ahmad AE; Hirata H; Kawakami K; Shahryari V; Saini S; Tanaka Y; Dahiya AV; Khatri G; Dahiya R
Carcinogenesis; 2009 Apr; 30(4):662-70. PubMed ID: 19221000
[TBL] [Abstract][Full Text] [Related]
40. Gene expression profiling of the synergy of 5-aza-2'-deoxycytidine and paclitaxel against renal cell carcinoma.
Han T; Shang D; Xu X; Tian Y
World J Surg Oncol; 2012 Sep; 10():183. PubMed ID: 22950635
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]